Long-term statin use in patients with lung cancer and dyslipidemia reduces the risk of death

Wen-Yen Huang; Chia-Hsiang Li; Cheng-Li Lin; Ji-An Liang

doi:10.18632/oncotarget.9906

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Long-term statin use in patients with lung cancer and dyslipidemia reduces the risk of death

Wen-Yen Huang, Chia-Hsiang Li, Cheng-Li Lin and Ji-An Liang _

PDF | HTML | How to cite

Oncotarget. 2016; 7:42208-42215. https://doi.org/10.18632/oncotarget.9906

Metrics: PDF 1928 views | HTML 1965 views | ?

Abstract

Wen-Yen Huang1,2, Chia-Hsiang Li3, Cheng-Li Lin4,5, Ji-An Liang6,7

1Department of Radiation Oncology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan

2Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan

3Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan

4Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan

5College of Medicine, China Medical University, Taichung, Taiwan

6Graduate Institute of Clinical Medical Science, College of Medicine, China Medical University, Taichung, Taiwan

7Department of Radiation Oncology, China Medical University Hospital, Taichung, Taiwan

Correspondence to:

Ji-An Liang, email: [email protected]

Keywords: lung cancer, statin, population-based case-control study

Received: March 15, 2016 Accepted: May 20, 2016 Published: June 07, 2016

ABSTRACT

Background: Clinical studies have obtained inconsistent results of statin use on cancer outcomes. This study investigated the association between statin use and lung cancer mortality.

Results: The use of statin decreased mortality (hazard ratio = 0.91; 95% confidence interval: 0.86–0.96; P < .01). The patients with a high cumulative defined daily dose of statin use before lung cancer diagnosis exhibited a low risk of mortality.

Materials and Methods: We conducted a population-based case-control study of patients with dyslipidemia. Among them, 6270 had used statins for at least 3 months before lung cancer diagnosis, and 6270 had never used statins.

Conclusions: We found that statin use can reduce lung cancer mortality. A further prospective study is necessary to confirm these findings.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 9906

Publication Alerts

Research Papers:

Long-term statin use in patients with lung cancer and dyslipidemia reduces the risk of death

Abstract